சுஷீல் கோடலி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

May 21, 2021
Transcatheter therapies for tricuspid valve disease continue to gain momentum, as evidenced by three studies presented at this week’s EuroPCR 2021: TRISCEND, TriBAND, and CLASP TR.
On the whole, the early data suggest these devices are a viable treatment for tricuspid regurgitation (TR), investigators told the meeting’s virtual audience, yet they also speak to the diverse approaches annular reduction, transcatheter edge-to-edge repair (TEER), and valve replacement aimed at addressing this clinical niche.
All three are manufactured by Edwards Lifesciences:
Thirty-day data from TRISCEND make the case for valve replacement, specifically with the Evoque device, in patients with symptomatic and at least moderate TR. ....

New York , United States , University Hospital , Mackram Eleid , Georg Nickenig , Susheel Kodali , Thomas Modine , Trialign Mitralign , Mara Gavazzoni , Edwards Lifesciences , Md University Hospital Bonn , American College Of Cardiology , Md University Hospital Zurich , Presbyterian Columbia University Irving Medical Center , Trivalve Registry , American College , Columbia University Irving Medical Center , Kansas City Cardiomyopathy Questionnaire , Mayo Clinic , University Hospital Bonn , University Hospital Zurich , Navigate Cardiac Structures , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் மருத்துவமனை , சுஷீல் கோடலி ,